Status:

UNKNOWN

Effects of Fasting Mimicking Diet (FMD) in Women With Polycystic Ovary Syndrome (PCOS)

Lead Sponsor:

University of Salento

Conditions:

Polycystic Ovarian Syndrome

Eligibility:

FEMALE

18-40 years

Phase:

NA

Brief Summary

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in reproductive-aged women, affecting 6-21% (depending on the applied diagnostic criteria) of this population worldwide. PCOS is char...

Detailed Description

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in reproductive-aged women, affecting 6-21% (depending on the applied diagnostic criteria) of this population worldwide. PCOS is char...

Eligibility Criteria

Inclusion

  • Female 18-40 years
  • BMI 20-40
  • Reproductive age women with PCOS diagnosis
  • Irregular menstrual cycles
  • Chronic oligo/anovulation defined as an intermenstrual interval of \>45 days
  • \< 8 menstrual cycles/year
  • evidence of either hyperandrogenemia (elevation of total or free testosterone above the normal range for women)
  • clinical hyerandrogenism (hirsutism and or acne)
  • 3 years from menarche
  • Agree to avoidance of pregnancy and to use barrier contraception for duration of study

Exclusion

  • • Clinically ascertained presence of type I and type II Diabetes
  • Pregnancy and/or nursing
  • Medication exclusion
  • Use of medications and/or supplements that influence either ovarian function or insulin sensitivity, within 2 months: including oral contraceptive pills, hormonal implants, anti-androgens, antipsychotics or antihypertensives metformin, glucocorticoids, and/or health food remedies other than multi-vitamins and calcium;
  • Subjects who are on oral contraception, metformin, or nutritional supplements must agree to discontinue these drugs and undergo an 8 week washout period before the tests are performed
  • Other drugs that cannot be suspended during the FMD phase
  • Alcohol usage more than 7 drinks/week

Key Trial Info

Start Date :

July 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2025

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT05196568

Start Date

July 1 2021

End Date

January 1 2025

Last Update

December 5 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Anna Maria Giudetti

Lecce, Italy, 73100